Tricyclic antidepressant toxicity: Difference between revisions

(Text replacement - "Alpha" to "α")
(23 intermediate revisions by 8 users not shown)
Line 3: Line 3:
*Used in depression and neuropathic pain
*Used in depression and neuropathic pain
*Serious toxicity is almost always seen within 6hr of ingestion
*Serious toxicity is almost always seen within 6hr of ingestion
*Coingestants often increase severity of toxicity
*Coingestants that impair metabolism through cytochrome P450 often increase severity of toxicity
**[[Cocaine]]can produce the same sodium blockade effect and exacerbate a TCA overdose
**[[Cocaine]] can produce the same sodium blockade effect and exacerbate as TCA overdose


===Ingestion amount===
===Ingestion amount===
Line 12: Line 12:


==Clinical Features==
==Clinical Features==
*Na Channel Blockade
*Na Channel Blockade (2-6 hours post ingestion)
**Negative inotropy, heart block, hypotension, ectopy
**Negative inotropy, [[heart block]], [[hypotension]], ectopy
*Anti-Histamine Effects
*Antihistamine Effects
**Sedation, coma
**Sedation, [[coma]]
*Anti-Muscarinic Effects
*Antimuscarinic Effects (early toxicity, within 2 hours)
**Central
**Central
***Agitation, delirium, confusion, [[hallucinations]]
***[[Agitation]], [[delirium]], [[confusion]], [[hallucinations]]
***Slurred speech, ataxia
***Slurred speech, [[ataxia]]
***Sedation, coma
***Sedation, [[coma]]
***[[Seizures]]
***[[Seizures]]
**Peripheral
**Peripheral
***Mydriasis, decreased secretions, dry skin, ileus, urinary retention
***Mydriasis, decreased secretions, dry skin, [[ileus]], [[urinary retention]]
***Tachycardia, hyperthermia
***[[Tachycardia]], [[hyperthermia]], [[hypertension]]
*α1 Receptor Blockade
*α<sub>1</sub> Receptor Blockade
**Sedation, orthostatic hypotension, miosis
**Sedation, orthostatic hypotension, miosis
*Inhibition of amine reuptake
*Inhibition of amine reuptake
**Sympathomimetic effects
**[[Sympathomimetic]] effects
**Myoclonus, hyperreflexia
**Myoclonus, hyperreflexia
**[[Serotonin Syndrome]] (only when used in combination with other serotonergic agents)
**[[Serotonin Syndrome]] (only when used in combination with other serotonergic agents)
Line 47: Line 47:
***Abnormal QRS morphology (deep slurred S wave in I and AVL)
***Abnormal QRS morphology (deep slurred S wave in I and AVL)
***Threshold of QRS>100 for seizures
***Threshold of QRS>100 for seizures
***Threshold of QRS>160 for ventricular dysrhymthmias
***Threshold of QRS>160 for ventricular dysrhythmias
**[[RBBB]]
**[[RBBB]]
**[[Right axis deviation]] (of terminal 40ms)<ref>Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. Aug 1995;26(2):195-201</ref>
**[[Right axis deviation]] (of terminal 40ms)<ref>Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. Aug 1995;26(2):195-201</ref>
Line 55: Line 55:
**Brugada pattern (15%)<ref>Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med. May 16 2002;346(20):1591-2</ref><ref>Monteban-Kooistra WE, van den Berg MP, Tulleken JE. Brugada electrocardiographic pattern elicited by cyclic antidepressants overdose. Intensive Care Med. Feb 2006;32(2):281-5</ref>
**Brugada pattern (15%)<ref>Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med. May 16 2002;346(20):1591-2</ref><ref>Monteban-Kooistra WE, van den Berg MP, Tulleken JE. Brugada electrocardiographic pattern elicited by cyclic antidepressants overdose. Intensive Care Med. Feb 2006;32(2):281-5</ref>
[[File:TCA_Toxicity.jpg|thumb|ECG in TCA toxicity]]
[[File:TCA_Toxicity.jpg|thumb|ECG in TCA toxicity]]
*An urine positive test result suggests only use of a TCA or another drug that cross-reacts with the screen (antimuscarinic, antipsychotic, carbamazepine, etc.)
*Quantitative serum level does not correlate with severity of illness


==Management==
==Management==
===GI Decontamination===
===GI Decontamination===
*[[Gastric lavage]] if <1hr after ingestion
*There is no role for [[Gastric lavage]]
*[[Activated charcoal]] 1gm/kg x1
*[[Activated charcoal]] 1gm/kg x1 if <1 hour and patient awake and cooperative without signs of toxicity


===Cardiac Toxicity<ref>Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24(3):205-14</ref>===
===Cardiac Toxicity<ref>Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24(3):205-14</ref>===
Line 67: Line 69:
*Initial Dosing:
*Initial Dosing:
**Give 1-2 mEq/kg as rapid IVP; may repeat as necessary (stop if pH > 7.50-7.55)
**Give 1-2 mEq/kg as rapid IVP; may repeat as necessary (stop if pH > 7.50-7.55)
**May give as 3ampules (132 mEq) of 8.4% NaHCO3
**May give as 3 ampules of 8.4% NaHCO3 (150 mEq) or 7.5% NaHCO3 (134 mEq)
*Infusion Dosing<ref>Seger DL, Hantsch C, Zavoral T, Wrenn K. Variability of recommendations for serum alkalinization in tricyclic antidepressant overdose: a survey of U.S. Poison Center medical directors. J Toxicol Clin Toxicol. 2003;41(4):331-8</ref>
*Infusion Dosing<ref>Seger DL, Hantsch C, Zavoral T, Wrenn K. Variability of recommendations for serum alkalinization in tricyclic antidepressant overdose: a survey of U.S. Poison Center medical directors. J Toxicol Clin Toxicol. 2003;41(4):331-8</ref>
**Mix 125-150 mEq of NaHCO3 in 1L of D5W; infuse at 250 mL/hr
**Mix 125-150 mEq of NaHCO3 in 1L of D5W; infuse at 250 mL/hr
Line 75: Line 77:
**May continue for 12-24hrs due to the drugs redistribution from tissue
**May continue for 12-24hrs due to the drugs redistribution from tissue
*Treatment Monitoring
*Treatment Monitoring
**Monitor for volume overload, hypokalemia, hypernatremia, metabolic alkalosis
**Monitor for volume overload, hypocalcemia, hypokalemia, hypernatremia, metabolic alkalosis
**Aggressively replace serum electrolytes


====Hyperventilation====
====Hyperventilation====
Line 82: Line 85:


====[[Lidocaine]]====
====[[Lidocaine]]====
*At 1.5mg/kg, consider lidocaine for ventricular dysrhythmias if NaHCO<sub>3</sub> alone is ineffective
*At 1.5 mg/kg, consider lidocaine for ventricular dysrhythmias if NaHCO<sub>3</sub> alone is ineffective
;NOTE: avoid IA, IB, IC antiarrhythmics, Beta-Blockers, and Calcium Channel Blockers
*Competitively inhibits sodium channel blockade effects of TCAs
;NOTE: Avoid IA, IC antiarrhythmics, Beta-Blockers, Calcium Channel Blockers, and amiodarone


====[[Phenytoin]]====
====[[Phenytoin]]====
Line 90: Line 94:
====Synchronized cardioversion====
====Synchronized cardioversion====
*Appropriate in patients with persistent unstable tachydysrhythmias
*Appropriate in patients with persistent unstable tachydysrhythmias
====NEVER Use [[Physostigmine]]====
*'''''NEVER''''' use [[physostigmine]] in TCA overdose as the combination leads to lethal bradyarrhythmias<ref>Schneider G. Never Use Physostigmine in a TCA Overdose. Emergency Medicine News: May 2003 - Volume 25 - Issue 5 - p 44.</ref>
**Due to dose dependent AV blockade by physostigmine
**TCA toxicity and physostigmine interact synergistically to cause AV conduction delays


===[[Seizures]]===
===[[Seizures]]===
Line 99: Line 108:
*After repeat fluid boluses and with sodium load from NaHCO<sub>3</sub> norepinepherine should be the first line vasopressor
*After repeat fluid boluses and with sodium load from NaHCO<sub>3</sub> norepinepherine should be the first line vasopressor
*ECMO is a successful adjunct for refractory hypotension after maximal therapy has failed
*ECMO is a successful adjunct for refractory hypotension after maximal therapy has failed
*May also consider [[hypertonic saline|hypertonic 3% saline]] for refractory hypotension
*May also consider 200 ml of [[hypertonic saline|hypertonic 3% saline]] for refractory hypotension and ventricular dysrhythmias despite maximal alkalinization (pH > 7.55)


===Dialysis===
===Dialysis===
Not useful for enhancing elimination due to the large volume of distribution and high lipid solubility
*Not useful for enhancing elimination due to the large volume of distribution and high lipid solubility
 
===[[Intralipid]]===
*1.5 mL/kg bolus over 2-3 minutes if life-threatening toxicity refractory to bicarbonate administration
*May be repeated once in 5 minutes if no improvement, followed by an infusion of 0.25 ml/kg/min for 15-30 minutes


==Disposition==
==Disposition==

Revision as of 19:40, 20 January 2020

Background

  • Abbreviation: TCA
  • Used in depression and neuropathic pain
  • Serious toxicity is almost always seen within 6hr of ingestion
  • Coingestants that impair metabolism through cytochrome P450 often increase severity of toxicity
    • Cocaine can produce the same sodium blockade effect and exacerbate as TCA overdose

Ingestion amount

  • <1mg/kg: Nontoxic
  • >10mg/kg: Life-threatening
  • >1gm: Commonly fatal

Clinical Features

Differential Diagnosis

Anticholinergic toxicity Causes

Sodium Channel Blockade Toxidrome

Evaluation

ECG in TCA toxicity
  • An urine positive test result suggests only use of a TCA or another drug that cross-reacts with the screen (antimuscarinic, antipsychotic, carbamazepine, etc.)
  • Quantitative serum level does not correlate with severity of illness

Management

GI Decontamination

Cardiac Toxicity[5]

Sodium Bicarbonate

  • Indications:
    • QRS >100ms, terminal RAD >120 deg, Brugada pattern, ventricular dysrhythmias
  • Initial Dosing:
    • Give 1-2 mEq/kg as rapid IVP; may repeat as necessary (stop if pH > 7.50-7.55)
    • May give as 3 ampules of 8.4% NaHCO3 (150 mEq) or 7.5% NaHCO3 (134 mEq)
  • Infusion Dosing[6]
    • Mix 125-150 mEq of NaHCO3 in 1L of D5W; infuse at 250 mL/hr
  • Treatment Goal:
    • QRS <100ms
    • pH 7.50-7.55
    • May continue for 12-24hrs due to the drugs redistribution from tissue
  • Treatment Monitoring
    • Monitor for volume overload, hypocalcemia, hypokalemia, hypernatremia, metabolic alkalosis
    • Aggressively replace serum electrolytes

Hyperventilation

  • Consider in patients unable to tolerate NaHCO3 (renal failure, pulm/cerebral edema)
  • Hyperventilate to pH of 7.50 - 7.55 (same as bicarb administration)

Lidocaine

  • At 1.5 mg/kg, consider lidocaine for ventricular dysrhythmias if NaHCO3 alone is ineffective
  • Competitively inhibits sodium channel blockade effects of TCAs
NOTE
Avoid IA, IC antiarrhythmics, Beta-Blockers, Calcium Channel Blockers, and amiodarone

Phenytoin

  • Consider for ventricular dysrhythmias resistant to NaHCO3 and lidocaine

Synchronized cardioversion

  • Appropriate in patients with persistent unstable tachydysrhythmias

NEVER Use Physostigmine

  • NEVER use physostigmine in TCA overdose as the combination leads to lethal bradyarrhythmias[7]
    • Due to dose dependent AV blockade by physostigmine
    • TCA toxicity and physostigmine interact synergistically to cause AV conduction delays

Seizures

Hypotension

  • After repeat fluid boluses and with sodium load from NaHCO3 norepinepherine should be the first line vasopressor
  • ECMO is a successful adjunct for refractory hypotension after maximal therapy has failed
  • May also consider 200 ml of hypertonic 3% saline for refractory hypotension and ventricular dysrhythmias despite maximal alkalinization (pH > 7.55)

Dialysis

  • Not useful for enhancing elimination due to the large volume of distribution and high lipid solubility

Intralipid

  • 1.5 mL/kg bolus over 2-3 minutes if life-threatening toxicity refractory to bicarbonate administration
  • May be repeated once in 5 minutes if no improvement, followed by an infusion of 0.25 ml/kg/min for 15-30 minutes

Disposition

  • Consider discharging patients who remain asymptomatic after 6hr of observation
  • Patients with decreased level of consciousness or seizures should be admitted to ICU

See Also

Video

{{#widget:YouTube|id=rMVw4ImwNDo}}

References

  1. Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2015;81(3):516-24.
  2. Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. Aug 1995;26(2):195-201
  3. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med. May 16 2002;346(20):1591-2
  4. Monteban-Kooistra WE, van den Berg MP, Tulleken JE. Brugada electrocardiographic pattern elicited by cyclic antidepressants overdose. Intensive Care Med. Feb 2006;32(2):281-5
  5. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24(3):205-14
  6. Seger DL, Hantsch C, Zavoral T, Wrenn K. Variability of recommendations for serum alkalinization in tricyclic antidepressant overdose: a survey of U.S. Poison Center medical directors. J Toxicol Clin Toxicol. 2003;41(4):331-8
  7. Schneider G. Never Use Physostigmine in a TCA Overdose. Emergency Medicine News: May 2003 - Volume 25 - Issue 5 - p 44.